Citations

Clear

9 citation(s) found for "Koch, David".

Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites
Bajaj, Jasmohan S. , Reddy, K. Rajender , Keaveny, Andrew P. , Porayko, Michael K. , Koch, David , Thuluvath, Paul J. , Angeli, Paolo, Janardhan, Sujit , Zhang, Jeffrey , Clausen, Susan, Dauphinée, Elisa, Palumbo, Joseph, Markham, Penelope , Weinberg, Ethan M , Rajender Reddy, K , Keaveny, Andrew P , Porayko, Michael K , Koch, David , Angeli, Paolo , Orman, Eric S , Palumbo, Joseph M , Weinberg, Ethan M. , Simonetto, Douglas A. , Angeli, Paolo , Orman, Eric S. , Clausen, Susan

Mayo Clinic

Liver Transplantation | April 24, 2025 | Volume: 31 | Issue: 10 | Pages: 1202-1214

10.1097/lvt.0000000000000623 | PMID 40272365 Get It

Refractory ascites often requires therapeutic paracentesis, which is associated with potential risks and diminished quality of life. Terlipressin is a vasopressin analog that is indicated for i.v. bolus injection for hepatorenal syndrome, with the potential to reduce large-volume ascites and its complications. Continuous infusion of terlipressin is associated with fewer adverse effects than bolus dosing. The efficacy and safety of continuous infusion of a novel liquid formulation of terlipressin acetate (BIV201) were evaluated in this open-label phase 2 study. Patients with cirrhosis and refractory ascites were randomly assigned (2:1) to receive two 28-day cycles of continuous infusion BIV201 plus standard of care (SOC) separated by a ≤56-day washout (n=10), or SOC alone (n=5). Data analysis was limited by the small sample size and confounded by a potential interaction with gabapentinoids in the BIV201+SOC group. Nonetheless, there were differences in favor of BIV201+SOC versus SOC in the coprimary efficacy endpoints and several quality of life assessments. The beneficial effects of BIV201 on liver complications (mean: 90% CI; BIV201-completers=2.87: 1.51; 5.46 vs. SOC=2.38: 1.20; 4.73) and the change in cumulative ascites (mean: 90% CI; BIV201-completers=−10.76: −26.51; 5.00 vs. SOC=−4.99: −21.95; 11.97) were more pronounced versus SOC in the 5 BIV201+SOC patients who completed both treatment cycles. There were also greater improvements in exploratory quality of life assessments and the percent change in therapeutic paracenteses with BIV201+SOC (−27.94±41.80) versus SOC (−16.67±45.64). Despite the high rate of hyponatremia in the BIV201+SOC group (4/10 patients), the safety profile suggested that continuous BIV201 infusion was well tolerated. These findings support further development of BIV201 in confirmatory trials.
Antifouling Immunomodulatory Copolymer Architectures That Inhibit the Fibrosis of Implants
Jeang, William J. , Jiang, Alexis L., Bose, Suman , Collins, Evan , McMullen, Patrick , Rosenboom, Jan‐Georg , Lathwal, Sushil , Langer, Robert , Anderson, Daniel G , Wong, Bryan Matthew , Zhao, Yichao , Manan, Rajith S. , Langer, Róbert , Anderson, Daniel G.

Mayo Clinic

Advanced Materials | December 25, 2024 | Volume: 37 | Issue: 7 | Pages: No page available

10.1002/adma.202414743 | PMID 39722171 Get It

Abstract Immune reactions to medical implants often lead to encapsulation by fibrotic tissue and impaired device function. This process is thought to initiate by protein adsorption, which enables immune cells to attach and mount an inflammatory response. Previously, several antifibrotic materials have been either designed to reduce protein adsorption or discovered via high‐throughput screens (HTS) to favorably regulate inflammation. The present work introduces antifouling immunomodulatory (AIM) copolymer coatings, which combine both strategies to effectively enhance implant protection. AIM copolymers synergistically integrate zwitterionic moieties to resist protein fouling, HTS‐derived antifibrotics for immunomodulation, and silane monomers for grafting to diverse substrates including elastomers, ceramics, and metals. Interestingly, simply combining these monomers into conventional random or block copolymer architectures yielded no significant advantage over homopolymers. By contrast, an unusual polymer chain architecture — a zwitterionic block flanked by a mixed zwitterionic immunomodulatory segment — showed superior fibrosis resistance in both peritoneal and subcutaneous sites over one month in immunocompetent mice. This architecture also improved the performance of two different HTS‐derived antifibrotic monomers, suggesting that tailoring AIM architectures may broadly complement immunomodulatory chemistries and provide a versatile approach to improving implant longevity.
Silicone cryogel skeletons enhance the survival and mechanical integrity of hydrogel-encapsulated cell therapies
Jeang, William J. , Bochenek, Matthew A. , Bose, Suman , Zhao, Yichao , Yang, Jiawei , Jiang, Alexis L., Langer, Róbert , Anderson, Daniel G. , Yang, Jiawei , Langer, Robert , Anderson, Daniel G , Wong, Bryan M.

Mayo Clinic

Science Advances | April 5, 2024 | Volume: 10 | Issue: 14 | Pages: No page available

10.1126/sciadv.adk5949 | PMID 38578991 Get It

The transplantation of engineered cells that secrete therapeutic proteins presents a promising method for addressing a range of chronic diseases. However, hydrogels used to encase and protect non-autologous cells from immune rejection often suffer from poor mechanical properties, insufficient oxygenation, and fibrotic encapsulation. Here, we introduce a composite encapsulation system comprising an oxygen-permeable silicone cryogel skeleton, a hydrogel matrix, and a fibrosis-resistant polymer coating. Cryogel skeletons enhance the fracture toughness of conventional alginate hydrogels by 23-fold and oxygen diffusion by 2.8-fold, effectively mitigating both implant fracture and hypoxia of encapsulated cells. Composite implants containing xenogeneic cells engineered to secrete erythropoietin significantly outperform unsupported alginate implants in therapeutic delivery over 8 weeks in immunocompetent mice. By improving mechanical resiliency and sustaining denser cell populations, silicone cryogel skeletons enable more durable and miniaturized therapeutic implants.
Performance of Three Anti-SARS-CoV-2 Anti-S and One Anti-N Immunoassays for the Monitoring of Immune Status and Vaccine Response
Zhang, Y. Victoria , Kumánovics, Attila , Wiencek, Joesph R , Melanson, Stacy E.F. , Love, Tanzy , Wu, Alan H.B. , Zhao, Zhen , Koch, David D., Apple, Fred S. , Ondracek, Caitlin R. , Christenson, Robert H. , Wiencek, Joesph , Zhang, Y. Victoria, Meng, Qing H.

Mayo Clinic

Viruses | February 14, 2024 | Volume: 16 | Issue: 2 | Pages: 292

10.3390/v16020292 | PMID 38400067 Get It

This study aimed to evaluate and compare the performance of three anti-S and one anti-N assays that were available to the project in detecting antibody levels after three commonly used SARS-CoV-2 vaccines (Pfizer, Moderna, and Johnson & Johnson). It also aimed to assess the association of age, sex, race, ethnicity, vaccine timing, and vaccine side effects on antibody levels in a cohort of 827 individuals. In September 2021, 698 vaccinated individuals donated blood samples as part of the Association for Diagnostics & Laboratory Medicine (ADLM) COVID-19 Immunity Study. These individuals also participated in a comprehensive survey covering demographic information, vaccination status, and associated side effects. Additionally, 305 age- and gender-matched samples were obtained from the ADLM 2015 sample bank as pre-COVID-19-negative samples. All these samples underwent antibody level analysis using three anti-S assays, namely Beckman Access SARS-CoV-2 IgG (Beckman assay), Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG (Ortho assay), Siemens ADVIA Centaur SARS-CoV-2 IgG (Siemens assay), and one anti-N antibody assay: Bio-Rad Platelia SARS-CoV-2 Total Ab assay (BioRad assay). A total of 827 samples (580 COVID-19 samples and 247 pre-COVID-19 samples) received results for all four assays and underwent further analysis. Beckman, Ortho, and Siemens anti-S assays showed an overall sensitivity of 99.5%, 97.6%, and 96.9%, and specificity of 90%, 100%, and 99.6%, respectively. All three assays indicated 100% sensitivity for individuals who received the Moderna vaccine and boosters, and over 99% sensitivity for the Pfizer vaccine. Sensitivities varied from 70.4% (Siemens), 81.5% (Ortho), and 96.3% (Beckman) for individuals who received the Johnson & Johnson vaccine. BioRad anti-N assays demonstrated 46.2% sensitivity and 99.25% specificity based on results from individuals with self-reported infection. The highest median anti-S antibody levels were measured in individuals who received the Moderna vaccine, followed by Pfizer and then Johnson & Johnson vaccines. Higher anti-S antibody levels were significantly associated with younger age and closer proximity to the last vaccine dose but were not associated with gender, race, or ethnicity. Participants with higher anti-S levels experienced significantly more side effects as well as more severe side effects (e.g., muscle pain, chills, fever, and moderate limitations) (p < 0.05). Anti-N antibody levels only indicated a significant correlation with headache. This study indicated performance variations among different anti-S assays, both among themselves and when analyzing individuals with different SARS-CoV-2 vaccines. Caution should be exercised when conducting large-scale studies to ensure that the same platform and/or assays are used for the most effective interpretation of the data.
Large-Scale Scientific Study Led by a Professional Organization during the COVID-19 Pandemic: Operations, Best Practices, and Lessons Learned
Ondracek, Caitlin R. , Melanson, Stacy E.F. , Doan, Loretta, Schulz, Karen , Kleinman, Stefanie, Zhao, Zhen , Kumánovics, Attila , Wu, Alan H.B. , Wiencek, Joesph R , Meng, Qing H. , Apple, Fred S. , Koch, David D., Vesper, Hubert W. , Pokuah, Fidelia, Bryksin, Janetta, Myers, Gary L., Christenson, Robert H. , Zhang, Y Victoria , Wiencek, Joesph , Ondracek, Caitlin R , Zhang, Y Victoria

Mayo Clinic

The Journal of Applied Laboratory Medicine | December 7, 2023 | Volume: 9 | Issue: 2 | Pages: 371-385

10.1093/jalm/jfad089 | PMID 38059919 Get It

Abstract In 2021, the Association for Diagnostics & Laboratory Medicine (ADLM) (formerly the American Association for Clinical Chemistry [AACC]) developed a scientific study that aimed to contribute to the understanding of SARS-CoV-2 immunity during the evolving course of the pandemic. This study was led by a group of expert member volunteers and resulted in survey data from 975 individuals and blood collection from 698 of those participants. This paper describes the formulation and execution of this large-scale scientific study, encompassing best practices and insights gained throughout the endeavor.
T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection
Zhao, Zhen , Kumánovics, Attila , Love, Tanzy , Melanson, Stacy E.F. , Wu, Alan H.B. , Wiencek, Joesph R , Apple, Fred S. , Ondracek, Caitlin R. , Koch, David D., Christenson, Robert H. , Zhang, Yan Victoria, Wiencek, Joesph , Ondracek, Caitlin R , Meng, Qing H.

Mayo Clinic

Viruses | March 9, 2023 | Volume: 15 | Issue: 3 | Pages: 709

10.3390/v15030709 | PMID 36992418 Get It

Objectives: The objective of this prospective study was to investigate the role of adaptive immunity in response to SARS-CoV-2 vaccines. Design and Methods: A cohort of 677 vaccinated individuals participated in a comprehensive survey of their vaccination status and associated side effects, and donated blood to evaluate their adaptive immune responses by neutralizing antibody (NAb) and T cell responses. The cohort then completed a follow-up survey to investigate the occurrence of breakthrough infections. Results: NAb levels were the highest in participants vaccinated with Moderna, followed by Pfizer and Johnson & Johnson. NAb levels decreased with time after vaccination with Pfizer and Johnson & Johnson. T cell responses showed no significant difference among the different vaccines and remained stable up to 10 months after the study period for all vaccine types. In multivariate analyses, NAb responses (<95 U/mL) predicted breakthrough infection, whereas previous infection, the type of vaccine, and T cell responses did not. T cell responses to viral epitopes (<0.120 IU/mL) showed a significant association with the self-reported severity of COVID-19 disease. Conclusion: This study provides evidence that NAb responses to SARS-CoV-2 vaccination correlate with protection against infection, whereas the T cell memory responses may contribute to protection against severe disease but not against infection.
Acute Liver Failure: Biomarkers Evaluated by the Acute Liver Failure Study Group
Rakela, Jorge , Karvellas, Constantine , Koch, David , Vegunta, Suneela , Lee, William M. , Rakela, Jorge , Karvellas, Constantine , Koch, David

Mayo Clinic

Clinical and Translational Gastroenterology | January 30, 2023 | Volume: 14 | Issue: 4 | Pages: e00565

10.14309/ctg.0000000000000565 | PMID 36716224 Get It

There has been a growing interest in identifying prognostic biomarkers that alone or with available prognostic models (King’s College Criteria, KCC; MELD and ALFSG Prognostic Index) would improve prognosis in acute liver failure (ALF) patients being assessed for liver transplantation. The Acute Liver Failure Study Group (ALFSG) has evaluated 15 potential prognostic biomarkers: serum AFP; apoptosis-associated proteins; serum actin-free Gc-globulin; serum glycodeoxycholic acid; sRAGE/RAGE ligands; plasma osteopontin; circulating MBL, M-, L-, H-ficolin and CL-1; plasma galectin-9; serum FABP1; serum Lct2; miRNAs; factor V; thrombocytopenia, and sCD163. The ALFSG also has reported on 4 susceptibility biomarkers: keratins 8 and 18 (K8/K18) gene variants; polymorphisms of genes encoding putative APAP-metabolizing enzymes ( UGT1A1 , UGT 1A0 , UGT 2B15 , SULT1A1 , CYP2E1 , and CYP3A5 ) as well as CD44 and BHMT1 ; single nucleotide polymorphisms (SNPs) of genes associated with human behavior, rs2282018 in the arginine vasopressin ( AVP ) gene and rs11174811 in the AVP receptor 1A gene. Finally, rs2277680 of the CSCL16 gene in HBV-ALF patients. In conclusion, we have reviewed the prognostic and susceptibility biomarkers studied by the ALFSG. We suggest that a better approach to predicting the clinical outcome of an ALF patient will require a combination of biomarkers of pathogenic processes such as cell death, hepatic regeneration, and degree of inflammation that could be incorporated into prognostic models such as KCC, MELD or ALFSG PI.
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Ellenberg, Susan S. , Krowka, Michael J. , Goldberg, David S. , Vargas, Hugo E. , Koch, David , Sharkoski, Tiffany, Al‐Naamani, Nadine , Fox, Alyson N. , Levitsky, Joshua, Oh, Jae K. , Lin, Grace , Song, Nianfu, Mottram, Carl, Doyle, Margaret F. , Gupta, Samir , Fallon, Michael B. , Vargas, Hugo, Vargas, Hugo E , Al-Naamani, Nadine , Kawut, Steven M. , Brown, Robert S. , Song, Nianfu, Kaplan, David E. , Koch, David

Mayo Clinic

Liver Transplantation | February 28, 2019 | Volume: 25 | Issue: 8 | Pages: 1155-1164

10.1002/lt.25438 | PMID 30816637 Get It

The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown. We aimed to determine the effect of sorafenib on the alveolar‐arterial oxygen gradient (AaPO2) at 3 months in patients with HPS. We performed a randomized, double‐blind, placebo‐controlled parallel trial of sorafenib in patients with HPS at 7 centers. A total of 28 patients with HPS were randomized to sorafenib 400 mg by mouth daily or a matching placebo in a 1:1 ratio. We found no statistically significant difference in the median change in AaPO2 from baseline to 12 weeks between the patients allocated to sorafenib (4.5 mm Hg; IQR, –3.8 to 7.0 mm Hg) and those allocated to placebo (–2.4 mm Hg; IQR, –4.8 to 8.2 mm Hg; P = 0.70). There was also no difference between the groups in terms of degree of intrapulmonary shunting by contrast echocardiography. Sorafenib significantly reduced circulating levels of angiogenic markers, including vascular endothelial growth factor receptors (P < 0.01) and TIE2‐expressing M2 monocytes (P = 0.03), but it reduced the mental component scores of the Short Form 36 (P = 0.04), indicating a worse quality of life. In conclusion, sorafenib did not change the AaPO2 or other disease markers at 3 months in patients with HPS. Alternative antiangiogenic therapies or treatments targeting other pathways should be investigated.